ArticleAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2017
End Points for Clinical Trials in Acute Kidney Injury.
Article in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Randomized trial of activated vitamin D for acute kidney injury prevention in critically ill patients.JCI insight · 2025Trial
- Trial
- Biochemical phenotypes of acute kidney injury and their association with major adverse kidney events.Renal failure · 2026Article
- Electroacupuncture-inspired neuroimmune modulation in sepsis: evidence appraisal and ICU trial-design priorities.Frontiers in medicine · 2026Review
- Cell and extracellular vesicle therapies for AKI in critical care: clinical translation, organ-support integration, and lessons learned.Frontiers in medicine · 2026Review
- Impact of aminoglycosides on survival rate and renal outcomes in patients with urosepsis: a multicenter retrospective study.Annals of intensive care · 2025Article
- Patient Preferences and Priorities for the Design of an Acute Kidney Injury Prevention Trial: Findings from a Consensus Workshop.Kidney360 · 2024Article
- Recommendations for clinical trial design in acute kidney injury from the 31st acute disease quality initiative consensus conference. A consensus statement.Intensive care medicine · 2024Article
- Derivation and external validation of a simple risk score for predicting severe acute kidney injury after intravenous cisplatin: cohort study.BMJ (Clinical research ed.) · 2024Article
- Combined Angiotensin Inhibition for CKD: The Truth Is Rarely Pure and Never Simple.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2024Article
- High-dose IV magnesium in mesothelioma patients receiving surgery with hyperthermic intraoperative cisplatin: Pilot studies and design of a phase II randomized clinical trial.Journal of surgical oncology · 2023Article
- Longer time to recovery from acute kidney injury is associated with major adverse kidney events in patients with cirrhosis.Alimentary pharmacology & therapeutics · 2023Article
- Development and validation of outcome prediction models for acute kidney injury patients undergoing continuous renal replacement therapy.Frontiers in medicine · 2022Article
- AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19.Journal of the American Society of Nephrology : JASN · 2021Article
- SEA-MAKE score as a tool for predicting major adverse kidney events in critically ill patients with acute kidney injury: results from the SEA-AKI study.Annals of intensive care · 2020Article
- Prevention of Cardiac Surgery-Associated Acute Kidney Injury: A Review of Current Strategies.Anesthesiology clinics · 2019Review
- Preconditioning against renal ischaemia reperfusion injury: the failure to translate to the clinic.Journal of nephrology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Acute kidney injury (AKI) is an increasingly common and feared complication in hospitalized patients. The selection of appropriate primary and secondary end points is critical to the design and eventual success of clinical trials aimed at preventing and treating AKI. In this article, we provide an overview of AKI definitions and suggestions on the rational selection of end points for clinical trials in various settings, including the prevention of contrast-induced AKI, prevention of cardiac surgery-associated AKI, treatment of established AKI, and treatment of dialysis-requiring AKI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.